蒂巴尼布林在光化性角化病治疗中的实际疗效:专家共识和临床见解。

IF 2.3 4区 医学 Q2 DERMATOLOGY
Marco Ardigò, Giuseppe Argenziano, Elena Campione, Stefania Guida, Caterina Longo, Giuseppe Micali, Gianluca Nazzaro, Ketty Peris, Federico Venturi, Alessia Villani, Iris Zalaudek
{"title":"蒂巴尼布林在光化性角化病治疗中的实际疗效:专家共识和临床见解。","authors":"Marco Ardigò, Giuseppe Argenziano, Elena Campione, Stefania Guida, Caterina Longo, Giuseppe Micali, Gianluca Nazzaro, Ketty Peris, Federico Venturi, Alessia Villani, Iris Zalaudek","doi":"10.5826/dpc.1503a5921","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Tirbanibulin, a topical treatment for actinic keratosis (AK) with a novel antiproliferative mechanism of action, has demonstrated efficacy and a favorable tolerability profile in clinical trials and real-life studies. An insight into best-practice use of tirbanibulin in different clinical presentations of AK would be useful.</p><p><strong>Objectives: </strong>The aim of this article was to deliver advice, via expert consensus, on the optimal use of tirbanibulin in the real-life management of AK.</p><p><strong>Methods: </strong>A panel of 11 dermatologists with expertise in the treatment of AK convened to develop consensus statements about key aspects of tirbanibulin treatment in AK patients based on selected literature data and on their own clinical experience.</p><p><strong>Results: </strong>Two areas were examined and discussed: clinical assessment/diagnostic procedures and key aspects of tirbanibulin therapy. A total of 19 statements concerning clinical evaluation of AK patients, routine and advanced diagnostic instruments, patient selection, treatment modalities, and key messages for patient communication were drafted and voted on.</p><p><strong>Conclusion: </strong>Tirbanibulin should be considered as a first-line option for most patients with AK owing to its proven efficacy, good local and systemic tolerability, and a short treatment regimen of five days. All these factors encourage patient acceptability and treatment compliance. The favorable safety profile and tolerability of tirbanibulin also enable flexible therapeutic schedules, including repeated treatment cycles, if needed.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 3","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339078/pdf/","citationCount":"0","resultStr":"{\"title\":\"Real-World Efficacy of Tirbanibulin in Actinic Keratosis Treatment: Expert Consensus and Clinical Insights.\",\"authors\":\"Marco Ardigò, Giuseppe Argenziano, Elena Campione, Stefania Guida, Caterina Longo, Giuseppe Micali, Gianluca Nazzaro, Ketty Peris, Federico Venturi, Alessia Villani, Iris Zalaudek\",\"doi\":\"10.5826/dpc.1503a5921\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Tirbanibulin, a topical treatment for actinic keratosis (AK) with a novel antiproliferative mechanism of action, has demonstrated efficacy and a favorable tolerability profile in clinical trials and real-life studies. An insight into best-practice use of tirbanibulin in different clinical presentations of AK would be useful.</p><p><strong>Objectives: </strong>The aim of this article was to deliver advice, via expert consensus, on the optimal use of tirbanibulin in the real-life management of AK.</p><p><strong>Methods: </strong>A panel of 11 dermatologists with expertise in the treatment of AK convened to develop consensus statements about key aspects of tirbanibulin treatment in AK patients based on selected literature data and on their own clinical experience.</p><p><strong>Results: </strong>Two areas were examined and discussed: clinical assessment/diagnostic procedures and key aspects of tirbanibulin therapy. A total of 19 statements concerning clinical evaluation of AK patients, routine and advanced diagnostic instruments, patient selection, treatment modalities, and key messages for patient communication were drafted and voted on.</p><p><strong>Conclusion: </strong>Tirbanibulin should be considered as a first-line option for most patients with AK owing to its proven efficacy, good local and systemic tolerability, and a short treatment regimen of five days. All these factors encourage patient acceptability and treatment compliance. The favorable safety profile and tolerability of tirbanibulin also enable flexible therapeutic schedules, including repeated treatment cycles, if needed.</p>\",\"PeriodicalId\":11168,\"journal\":{\"name\":\"Dermatology practical & conceptual\",\"volume\":\"15 3\",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339078/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology practical & conceptual\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5826/dpc.1503a5921\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology practical & conceptual","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5826/dpc.1503a5921","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

蒂巴尼布林是一种局部治疗光化性角化病(AK)的药物,具有新型的抗增殖作用机制,在临床试验和现实生活研究中已经证明了其有效性和良好的耐受性。了解在不同的AK临床表现中使用蒂巴布林的最佳实践将是有用的。目的:这篇文章的目的是提供建议,通过专家共识,在现实生活中管理AK的最佳使用蒂巴尼布林。方法:一个由11名具有AK治疗专业知识的皮肤科医生组成的小组,根据选定的文献数据和他们自己的临床经验,就替巴布林治疗AK患者的关键方面制定共识声明。结果:研究和讨论了两个方面:临床评估/诊断程序和替巴布林治疗的关键方面。共起草和表决了19项关于AK患者临床评价、常规和先进诊断仪器、患者选择、治疗方式和患者沟通关键信息的声明。结论:替巴尼布林疗效可靠,局部和全身耐受性好,且治疗时间短,仅需5天,可作为大多数AK患者的一线治疗选择。所有这些因素都鼓励患者接受和治疗依从性。蒂巴尼布林良好的安全性和耐受性也使治疗方案灵活,如有需要,包括重复治疗周期。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Real-World Efficacy of Tirbanibulin in Actinic Keratosis Treatment: Expert Consensus and Clinical Insights.

Introduction: Tirbanibulin, a topical treatment for actinic keratosis (AK) with a novel antiproliferative mechanism of action, has demonstrated efficacy and a favorable tolerability profile in clinical trials and real-life studies. An insight into best-practice use of tirbanibulin in different clinical presentations of AK would be useful.

Objectives: The aim of this article was to deliver advice, via expert consensus, on the optimal use of tirbanibulin in the real-life management of AK.

Methods: A panel of 11 dermatologists with expertise in the treatment of AK convened to develop consensus statements about key aspects of tirbanibulin treatment in AK patients based on selected literature data and on their own clinical experience.

Results: Two areas were examined and discussed: clinical assessment/diagnostic procedures and key aspects of tirbanibulin therapy. A total of 19 statements concerning clinical evaluation of AK patients, routine and advanced diagnostic instruments, patient selection, treatment modalities, and key messages for patient communication were drafted and voted on.

Conclusion: Tirbanibulin should be considered as a first-line option for most patients with AK owing to its proven efficacy, good local and systemic tolerability, and a short treatment regimen of five days. All these factors encourage patient acceptability and treatment compliance. The favorable safety profile and tolerability of tirbanibulin also enable flexible therapeutic schedules, including repeated treatment cycles, if needed.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.40
自引率
0.00%
发文量
217
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信